Aridol News and Research

RSS
Aridol is a lung function test and the world's first approved indirect challenge test for asthma. The Aridol lung function test, developed by Australian researchers and Pharmaxis, helps doctors more accurately determine the severity of a patient's airways inflammation - a hallmark of asthma - and allow prescription of the right amount of medication. The 15-25 minute test uses powdered mannitol, which the patient inhales in increasing doses. In asthmatic patients, this causes the airways to narrow and contract, which is detected by measuring the amount of air a person can exhale in one second. The smaller the dose required to cause contraction, the more severe the patient's asthma.
CMS assigns J-code for Pharmaxis ARIDOL Bronchial Challenge Test Kit

CMS assigns J-code for Pharmaxis ARIDOL Bronchial Challenge Test Kit

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

European CHMP adopts positive opinion for Pharmaxis Bronchitol Marketing Authorisation

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

Pharmaxis to present ARIDOL Bronchial Challenge Test Kit at 2010 ACAAI

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

Pharmaxis announces combined results of Bronchitol Phase III trial for cystic fibrosis

Pharmaxis receives FDA approval to market ARIDOL Test Kit

Pharmaxis receives FDA approval to market ARIDOL Test Kit

FDA accepts Pharmaxis’ Aridol NDA for review

FDA accepts Pharmaxis’ Aridol NDA for review

Pharmaxis announces NDA filing for Aridol

Pharmaxis announces NDA filing for Aridol

Pharmaxis announces NDA filing for Aridol

Pharmaxis announces NDA filing for Aridol

Aridol authorised for sale in Germany

Aridol authorised for sale in Germany

Pharmaxis files for Korean marketing approval of its lung function test Aridol

Pharmaxis files for Korean marketing approval of its lung function test Aridol